Equity Profile

DNTH

Dianthus Therapeutics, Inc.

Health CareBiotechnology$4.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNTH Q2-2026 Earnings Preview

Context

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, the company aims to address unmet medical needs through advanced drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

In Q1-2026, Dianthus reported an EPS of -$0.85, which was better than the expected -$1.17, resulting in a positive surprise of 27%. The stock reacted positively, gaining 1.01% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious as there are no analyst estimates available for this quarter. The lack of management guidance adds to the uncertainty surrounding the earnings report.

Bull Case

If Dianthus can demonstrate significant progress in its drug development pipeline or show better-than-expected financial metrics, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its therapies, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug development pipeline?

Investors will be keen to understand any advancements or setbacks, as this will heavily influence future revenue potential.

How does the company plan to manage its expenses moving forward?

Cost management is crucial for biotech firms, especially those still in the development phase, and could impact investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Dianthus to achieve better-than-expected results due to recent advancements in its drug pipeline.

Supporting Evidence

The company's recent performance has shown a trend of beating EPS estimates, suggesting operational improvements.

Options pricing indicates a high expected move, which could reflect investor sentiment that is more optimistic than consensus.

The lack of analyst estimates may lead to a mispricing of risk, as the company could surprise the market positively.

Key Risk

If the company reports an EPS loss below -$0.70, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dianthus can effectively manage its costs while advancing its drug development, which is critical for its financial health.

Bull Confirmed If

A significant reduction in EPS loss, ideally below -$0.70, would indicate improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$1.00 could signal deeper issues within the company.

Pre-Earnings Positioning

Options Market

Implied Move

±23.01%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant move, indicating that investors anticipate volatility around the earnings report.

Options are pricing ±23.0% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

38.6%

Calls (5K)P/C Ratio: 0.19Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats expectations, history suggests the stock could rise by around 5.24%, confirming a positive outlook on its drug pipeline.

In-Line / Cautious

If results are in line with past performance, the stock may see muted movement as investors await clearer guidance.

Miss

Should the company miss expectations, history indicates a potential decline of about 4.47%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug development pipeline and any upcoming clinical trial results.
2Details on cost management strategies and operational efficiencies.
3Any partnerships or collaborations that could enhance market position.
4Insights into market demand for their therapies and competitive landscape.
5Management's outlook on future revenue growth and profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNTH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

In Q1-2026, Dianthus reported an EPS of -$0.85, which was better than the expected -$1.17, resulting in a positive surprise of 27%. The stock reacted positively, gaining 1.01% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious as there are no analyst estimates available for this quarter. The lack of management guidance adds to the uncertainty surrounding the earnings report.

Bull Case

If Dianthus can demonstrate significant progress in its drug development pipeline or show better-than-expected financial metrics, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its therapies, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug development pipeline?

Investors will be keen to understand any advancements or setbacks, as this will heavily influence future revenue potential.

How does the company plan to manage its expenses moving forward?

Cost management is crucial for biotech firms, especially those still in the development phase, and could impact investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Dianthus to achieve better-than-expected results due to recent advancements in its drug pipeline.

Supporting Evidence

The company's recent performance has shown a trend of beating EPS estimates, suggesting operational improvements.

Options pricing indicates a high expected move, which could reflect investor sentiment that is more optimistic than consensus.

The lack of analyst estimates may lead to a mispricing of risk, as the company could surprise the market positively.

Key Risk

If the company reports an EPS loss below -$0.70, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dianthus can effectively manage its costs while advancing its drug development, which is critical for its financial health.

Bull Confirmed If

A significant reduction in EPS loss, ideally below -$0.70, would indicate improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$1.00 could signal deeper issues within the company.

Pre-Earnings Positioning

Options Market

Implied Move

±23.01%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant move, indicating that investors anticipate volatility around the earnings report.

Options are pricing ±23.0% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

38.6%

Calls (5K)P/C Ratio: 0.19Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats expectations, history suggests the stock could rise by around 5.24%, confirming a positive outlook on its drug pipeline.

In-Line / Cautious

If results are in line with past performance, the stock may see muted movement as investors await clearer guidance.

Miss

Should the company miss expectations, history indicates a potential decline of about 4.47%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug development pipeline and any upcoming clinical trial results.
2Details on cost management strategies and operational efficiencies.
3Any partnerships or collaborations that could enhance market position.
4Insights into market demand for their therapies and competitive landscape.
5Management's outlook on future revenue growth and profitability.